NCT00069940View on ClinicalTrials.gov

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 2000

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2008

Conditions
Brain and Central Nervous System TumorsGastrointestinal Stromal TumorSarcoma
Interventions
BIOLOGICAL

sargramostim

BIOLOGICAL

telomerase: 540-548 peptide vaccine

Trial Locations (1)

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT00069940 - Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor | Biotech Hunter | Biotech Hunter